The Emerging Neurobiology of Psychedelics: Critical Periods, Metaplasticity, and Extracellular Matrix Remodeling.
Gül Dölen, Makenzie L Wilkinson
Annual review of neuroscience July 1, 2026 DOI: 10.1146/annurev-neuro-112723-045129 via PubMed
Summary
AI-generated from the abstractPsychedelics reopen critical periods, induce metaplasticity, and reorganize the extracellular matrix, which helps explain their diverse, durable, and context-dependent therapeutic effects. This neurobiological evidence challenges the biochemical imbalance model that has dominated translational neuroscience since the 1950s and supports a learning model that better accounts for psychedelics' unique therapeutic profile.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Ecm Critical period Extracellular matrix Learning Metaplasticity |
| Key finding | A unifying property of psychedelics is that they reopen critical periods, induce metaplasticity, and reorganize the extracellular matrix, supporting a learning model over the biochemical imbalance model. |
Abstract
Psychedelics are a broad category of compounds that induce altered states of consciousness. These drugs have shown remarkable promise for the treatment of debilitating disorders ranging from posttraumatic stress disorder to depression and addiction. Although early studies focused on linking binding targets of psychedelics to their therapeutic effects, these pharmacological and biochemical explanations fail to account for the diversity, durability, and context dependence of psychedelics' clinical and acute subjective effects. More recently, neurobiological explanations offer fresh insights and demonstrate that a unifying property of psychedelics is that these compounds reopen critical periods, induce metaplasticity, and reorganize the extracellular matrix. Here we review this evidence and argue that the neurobiological and therapeutic effects of psychedelics challenge the biochemical imbalance model that has dominated translational neuroscience since the 1950s and favor instead a learning model that better accounts for psychedelics' unique therapeutic profile.